Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

10.92
-0.1400-1.27%
Volume:292.67K
Turnover:3.21M
Market Cap:678.77M
PE:-8.74
High:11.35
Open:11.33
Low:10.77
Close:11.06
52wk High:11.45
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:0.37
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.65
PE(LYR):-6.91

Loading ...

Sagimet Biosciences grants 34,300 inducement stock options to new hires

Reuters
·
Jun 23

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged

TIPRANKS
·
Jun 18

Sagimet Biosciences Announces Board Changes and Director Elections

TIPRANKS
·
Jun 13

Sagimet Biosciences shareholders elect Class III directors at annual meeting

Reuters
·
Jun 13

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards

TIPRANKS
·
Jun 04

Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs

Reuters
·
Jun 04

UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults

THOMSON REUTERS
·
Jun 03

Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults

Reuters
·
May 27

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

GlobeNewswire
·
May 27

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Sagimet Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 19

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

TIPRANKS
·
May 19

Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer

Reuters
·
May 15

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 14

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

TIPRANKS
·
May 14

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 13

Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12